{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=carcinoembryonic+antigen+peptide+1", "query": { "intervention": "carcinoembryonic antigen peptide 1" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 11, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=carcinoembryonic+antigen+peptide+1&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-29T22:25:40.956Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05726864", "title": "A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma", "Colorectal Cancer", "KRAS G12D", "KRAS G12R", "KRAS G12V", "KRAS G12A", "KRAS G12C", "KRAS G12S", "KRAS G13D", "NRAS G12D", "NRAS G12R", "NRAS G12V", "NRAS G12C", "NRAS G12S" ], "interventions": [ { "name": "ELI-002 7P", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elicio Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 158, "start_date": "2023-04-14", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-09-29T22:25:40.956Z", "location_count": 28, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 21 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05726864" }, { "nct_id": "NCT05733689", "title": "Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastroesophageal Adenocarcinoma" ], "interventions": [ { "name": "FLOT", "type": "COMBINATION_PRODUCT" }, { "name": "FOLFOX", "type": "COMBINATION_PRODUCT" }, { "name": "FOLFIRI", "type": "COMBINATION_PRODUCT" }, { "name": "FOLFIRINOX", "type": "COMBINATION_PRODUCT" }, { "name": "PACLITAXEL with or without CARBOPLATIN", "type": "COMBINATION_PRODUCT" }, { "name": "DOCETAXEL and IRINOTECAN (alone or combined)", "type": "COMBINATION_PRODUCT" }, { "name": "NIVOLUMAB (alone or when added to a regimen above)", "type": "DRUG" }, { "name": "PEMBROLIZUMAB (alone or when added to a regimen above)", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG" ], "sponsor": "University of California, Irvine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2025-06-27", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-03-10", "last_synced_at": "2026-09-29T22:25:40.956Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05733689" }, { "nct_id": "NCT00217373", "title": "Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Solid Neoplasm" ], "interventions": [ { "name": "Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine", "type": "BIOLOGICAL" }, { "name": "Recombinant Interferon Alfa-2b", "type": "BIOLOGICAL" }, { "name": "Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine", "type": "BIOLOGICAL" }, { "name": "Sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2005-06", "completion_date": "2015-03", "has_results": false, "last_update_posted_date": "2015-04-20", "last_synced_at": "2026-09-29T22:25:40.956Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00217373" }, { "nct_id": "NCT03586869", "title": "QUILT-3.080: NANT Pancreatic Cancer Vaccine", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Aldoxorubicin HCl", "type": "DRUG" }, { "name": "ALT-803", "type": "BIOLOGICAL" }, { "name": "ETBX-011", "type": "BIOLOGICAL" }, { "name": "ETBX-021", "type": "BIOLOGICAL" }, { "name": "ETBX-051", "type": "BIOLOGICAL" }, { "name": "ETBX-061", "type": "BIOLOGICAL" }, { "name": "GI-4000", "type": "BIOLOGICAL" }, { "name": "GI-6207", "type": "BIOLOGICAL" }, { "name": "GI-6301", "type": "BIOLOGICAL" }, { "name": "haNK for infusion", "type": "BIOLOGICAL" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "nab-Paclitaxel", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Avelumab", "type": "BIOLOGICAL" }, { "name": "SBRT", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2018-07-17", "completion_date": "2019-08-01", "has_results": true, "last_update_posted_date": "2024-08-27", "last_synced_at": "2026-09-29T22:25:40.956Z", "location_count": 1, "location_summary": "El Segundo, California", "locations": [ { "city": "El Segundo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03586869" }, { "nct_id": "NCT00179309", "title": "Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "PANVAC-V", "type": "BIOLOGICAL" }, { "name": "PANVAC-F", "type": "BIOLOGICAL" }, { "name": "Sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 48, "start_date": "2005-09", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2014-07-15", "last_synced_at": "2026-09-29T22:25:40.956Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Houston, Texas", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00179309" }, { "nct_id": "NCT00057915", "title": "Vaccine Therapy in Treating Patients With Refractory Stage IV Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "CEA peptide 1-6D", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2003-09", "completion_date": "2006-09", "has_results": false, "last_update_posted_date": "2014-09-08", "last_synced_at": "2026-09-29T22:25:40.956Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00057915" }, { "nct_id": "NCT00004085", "title": "Radioimmunotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "yttrium Y 90 monoclonal antibody MN-14", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "RADIATION" ], "sponsor": "Garden State Cancer Center at the Center for Molecular Medicine and Immunology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "1998-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2011-06-22", "last_synced_at": "2026-09-29T22:25:40.956Z", "location_count": 3, "location_summary": "Belleville, New Jersey • Paterson, New Jersey • Philadelphia, Pennsylvania", "locations": [ { "city": "Belleville", "state": "New Jersey" }, { "city": "Paterson", "state": "New Jersey" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004085" }, { "nct_id": "NCT00203892", "title": "Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "modified CEA peptide (10mcg)", "type": "BIOLOGICAL" }, { "name": "modified CEA peptide (100mcg)", "type": "BIOLOGICAL" }, { "name": "modified CEA peptide (1000mcg)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2003-04", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2014-04-16", "last_synced_at": "2026-09-29T22:25:40.956Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00203892" }, { "nct_id": "NCT01273402", "title": "Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "TF2/IMP288", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2011-02", "completion_date": "2018-08", "has_results": false, "last_update_posted_date": "2021-08-16", "last_synced_at": "2026-09-29T22:25:40.956Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01273402" }, { "nct_id": "NCT00003434", "title": "Biological Therapy in Stage I, Stage II, or Stage III Surgically Resected Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "carcinoembryonic antigen peptide 1", "type": "BIOLOGICAL" }, { "name": "hepatitis B antigen peptide", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "1998-06", "completion_date": "2002-08", "has_results": false, "last_update_posted_date": "2014-02-10", "last_synced_at": "2026-09-29T22:25:40.956Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003434" } ] }